Zai Lab (09688) announced that its partner and study sponsor Amgen disclosed during its Q3 2025 earnings call on November 4, 2025, the discontinuation of the Phase 1b/3 FORTITUDE-102 clinical trial evaluating bemarituzumab combined with chemotherapy and nivolumab as first-line gastric cancer treatment. The decision followed an interim analysis by the Data Monitoring Committee indicating insufficient efficacy. For more Hong Kong stock market updates, visit the designated financial portal (search "Zhitong Caijing"). To join the Hong Kong stock investment community, contact the platform's customer service.